Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both

doi:10.4254/wjh.v16.i6.871

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5201)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

172

HTML

2788

Figures (1-1)

478

Sum=3438

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

251

Download

599

Sum=850

Publishing Process of This Article

Item

Count

Browse

191

Download

536

Sum=727

Jun 27, 2024 (publication date) through Feb 26, 2026

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Jun 27, 2024; 16(6): 871-877
Published online Jun 27, 2024. doi: 10.4254/wjh.v16.i6.871

Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both

Rochelle Wong, Li-Yun Yuan

Rochelle Wong, Li-Yun Yuan, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, United States

Author contributions: Wong R performed the literature review and wrote the manuscript; Yuan LY reviewed and revised the manuscript; and all authors have read and approved of the final manuscript.

Conflict-of-interest statement: The authors have no conflicts of interest to disclose.

Corresponding author: Rochelle Wong, MD, Doctor, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, 1510 San Pablo St. HC1-Suite 200, Los Angeles, CA 90033, United States. rochellewong15@gmail.com

Received: February 17, 2024
Revised: April 23, 2024
Accepted: April 29, 2024
Published online: June 27, 2024
Processing time: 123 Days and 19.1 Hours

Core Tip

Core Tip: Sarcopenia and metabolic dysfunction associated steatotic liver disease (MASLD) share a bidirectional relationship along the liver-muscle axis. With similar pathophysiology and shared risk factors, MASLD is a risk factor for sarcopenia, and vice versa. Early identification and adequate diagnosis are important. However, lack of consensus definition made it difficult to research outcomes. With the recently updated consensus definition for MASLD, researchers may now better identify proper cohorts for study. Consensus on gold standard techniques and muscle mass cutoffs to define sarcopenia are still needed. Future research may identify potential therapeutic targets along the shared liver-muscle axis that would improve outcomes for both sarcopenia and MASLD.